Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 4/2024

Open Access 01-04-2024 | Kidney Cancer | Review

Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update

Authors: Andrey Soares, Fernando Sabino Marques Monteiro, Karine Martins da Trindade, Adriano Gonçalves e Silva, Ana Paula Garcia Cardoso, André Deeke Sasse, André P. Fay, André Paternò Castello Dias Carneiro, Antonio Machado Alencar Junior, Augusto César de Andrade Mota, Bruno Santucci, Daniel da Motta Girardi, Daniel Herchenhorn, Daniel Vilarim Araújo, Denis Leonardo Jardim, Diogo Assed Bastos, Diogo Rodrigues Rosa, Fabio A. Schutz, Fábio Roberto Kater, Felipe da Silva Marinho, Fernando Cotait Maluf, Fernando Nunes Galvão de Oliveira, Fernando Vidigal, Igor Alexandre Protzner Morbeck, Jose Augusto Rinck Júnior, Leonardo Atem G. A. Costa, Manuel Caitano Dias Ferreira Maia, Manuela Zereu, Marcelo Roberto Pereira Freitas, Mariane Sousa Fontes Dias, Milena Shizue Tariki, Pamela Muniz, Patrícia Medeiros Milhomem Beato, Paulo Sérgio Moraes Lages, Pedro Isaacsson Velho, Ricardo Saraiva de Carvalho, Rodrigo Coutinho Mariano, Sandro Roberto de Araújo Cavallero, Thiago Martins Oliveira, Vinicius Carrera Souza, Oren Smaletz, Stênio de Cássio Zequi

Published in: Journal of Cancer Research and Clinical Oncology | Issue 4/2024

Login to get access

Abstract

Purpose

Renal cell carcinoma is an aggressive disease with a high mortality rate. Management has drastically changed with the new era of immunotherapy, and novel strategies are being developed; however, identifying systemic treatments is still challenging. This paper presents an update of the expert panel consensus from the Latin American Cooperative Oncology Group and the Latin American Renal Cancer Group on advanced renal cell carcinoma management in Brazil.

Methods

A panel of 34 oncologists and experts in renal cell carcinoma discussed and voted on the best options for managing advanced disease in Brazil, including systemic treatment of early and metastatic renal cell carcinoma as well as nonclear cell tumours. The results were compared with the literature and graded according to the level of evidence.

Results

Adjuvant treatments benefit patients with a high risk of recurrence after surgery, and the agents used are pembrolizumab and sunitinib, with a preference for pembrolizumab. Neoadjuvant treatment is exceptional, even in initially unresectable cases. First-line treatment is mainly based on tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs); the choice of treatment is based on the International Metastatic Database Consortium (IMCD) risk score. Patients at favourable risk receive ICIs in combination with TKIs. Patients classified as intermediate or poor risk receive ICIs, without preference for ICI + ICIs or ICI + TKIs. Data on nonclear cell renal cancer treatment are limited. Active surveillance has a place in treating favourable-risk patients. Either denosumab or zoledronic acid can be used for treating metastatic bone disease.

Conclusion

Immunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature.
Appendix
Available only for authorised users
Literature
Abreu D, Carvalhal G, Gueglio G et al (2021) Prognostic factors in de novo metastatic renal cell carcinoma: a report from the Latin American renal cancer group. JCO Glob Oncol 7:671–685PubMed
Albiges L, Gurney H, Atduev V et al (2023a) Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol 11:881
Albiges L, Powles T, Sharma A et al (2023b) CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC). J Clin Oncol 41(6):606
Alhalabi O, Wilson N, Ajufo H et al (2022) 2022) Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC. J Clin Oncol 40:356
Allaf M, Kim SE, Harshman LC et al (2022) Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. Ann Oncol 33:S808–S869
Amato R, Stepankiw M (2013) Evaluation of everolimus in renal cell cancer. Expert Opin Pharmacother 14(9):1229–1240PubMed
Amzal B, Fu S, Meng J, Lister J, Karcher H (2017) Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma. PLoS ONE 8:0184423
Auvray M, Auclin E, Barthelemy P et al (2019) Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. Eur J Cancer 108:33–40PubMed
Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L (2022) Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol 39(3):2022
Barata PC, De Liano AG, Mendiratta P et al (2018) The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. Br J Cancer 119(2):160–163PubMedPubMedCentral
Beckermann KE, Sharma D, Chaturvedi S et al (2017) Renal medullary carcinoma: establishing standards in practice. J Oncol Pract 13(7):414–421PubMedPubMedCentral
Bex A, Uzzo R, Karam JA et al (2022) LBA66 - IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection. Ann Oncol 33:S808–S869
Bimbatti D, Ciccarese C, Fantinel E et al (2018) Predictive role of changes in the tumor burden and international metastatic renal cell carcinoma database consortium class during active surveillance for metastatic renal cell carcinoma. Urol Oncol 36(12):526.e13-526.e18PubMed
Blas L, Roberti J, Petroni J, Reniero L, Cicora F (2019) Renal Medullary Carcinoma: a Report of the Current Literature. Curr Urol Rep 20:4PubMed
Burotto M, Powles T, Escudier B et al (2023) Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. J Clin Oncol 41:603
Caliò A, Segala D, Munari E, Brunelli M, Martignoni G (2019) MiT family translocation renal cell carcinoma: from the early descriptions to the current knowledge. Cancers (basel) 11(8):1110PubMed
Calvo E, Escudier B, Motzer RJ et al (2012) Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48(3):333–339PubMed
Cannady SB, Cavanaugh KA, Lee SY et al (2004) Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study. Int J Radiat Oncol Biol Phys 58(1):253–258PubMed
Chahoud J, Msaouel P, Campbell MT et al (2020) Nivolumab for the treatment of patients with metastatic non-clear cell renal cell carcinoma (nccRCC): a single-institutional experience and literature meta-analysis. Oncologist 25(3):252–258PubMed
Chen J, Zhou L, Liu X, Wen X, Li H, Li W (2020) Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis. Int J Clin Pharm 43(1):2–10PubMed
Choueiri TK, Escudier B, Powles T et al (2016) Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17(7):917–927PubMed
Choueiri TK, Halabi S, Sanford BL et al (2017) Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol 35(6):591–597PubMed
Choueiri TK, Larkin J, Pal S et al (2021a) Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO 6(3):100101
Choueiri TK, Powles T, Burotto M et al (2021b) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384(9):829–841PubMedPubMedCentral
Choueiri TK, Powles T, Albiges L et al (2023) Cabozantinib plus Nivolumab and Ipilimumab in renal-cell carcinoma. N Engl J Med 388(19):1767–1778PubMedPubMedCentral
Choueiri TK, Tomczak P, Park SH, et al (2021a) KEYNOTE-564 Investigators. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med 385(8):683–694.
Ciccarese C, Iacovelli R, Brunelli M et al (2017) Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. Eur J Cancer 83:237–246PubMed
Correa AF, Jegede OA, Haas NB et al (2021) Predicting disease recurrence, early progression, and overall survival following surgical resection for high-risk localized and locally advanced renal cell carcinoma. Eur Urol 80(1):20–31PubMedPubMedCentral
Dason S, Allard C, Sheridan-Jonah A et al (2013) Management of renal collecting duct carcinoma: a systematic review and the McMaster experience. Curr Oncol 20(3):e223-232PubMedPubMedCentral
Eisen T, Frangou E, Oza B et al (2020) Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the sorce randomized phase III intergroup trial. J Clin Oncol 38(34):4064–4075PubMedPubMedCentral
Emamekhoo H, Olsen MR, Carthon BC et al (2022) Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer 128(5):966–974PubMed
Escudier B, Motzer RJ, Dyer M et al (2022) 1459P - Analysis of long-term efficacy outcomes from the CheckMate 025 (CM 025) trial comparing nivolumab (NIVO) vs everolimus (EVE) based on ≥ 7 years (yrs) of follow-up in pre-treated patients (pts) with advanced renal cell carcinoma (aRCC). Ann Oncol 33:S660–S680
Fernández-Pello S, Hofmann F, Tahbaz R et al (2017) A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol 71(3):426–436PubMed
Fyfe G, Fisher RI, Rosenberg SA et al (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688PubMed
Gross-Goupil M, Kwon TG, Eto M et al (2018) Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 29(12):2371–2378PubMedPubMedCentral
Gupta R, Ornstein MC, Li H et al (2020) Clinical activity of Ipilimumab plus Nivolumab in patients with metastatic non-clear cell renal cell carcinoma. Clin Genitourin Cancer 18(6):429–435PubMed
Haanen JBAG, Larkin J, Choueiri TK et al (2023) Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. ESMO Open 8(3):101210PubMedPubMedCentral
Haas NB, Manola J, Uzzo RG et al (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387(10032):2008–2016PubMedPubMedCentral
Haas NB, Manola J, Dutcher JP et al (2017) Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial. JAMA Oncol 3(9):1249–1252PubMedPubMedCentral
Hanif A, Pandey M, Khan S, Attwood K, George S (2019) Metastatic sarcomatoid renal cell carcinoma treated with immune checkpoint inhibitors. Oncoimmunology 8(8):1606639PubMedPubMedCentral
Hansen HC, Janssen S, Schild SE, Rades D (2019) Estimating survival of patients with metastatic renal cell carcinoma receiving whole-brain radiotherapy with a new tool. Anticancer Res 39(4):2091–2095PubMed
Harrison MR, Costello BA, Bhavsar NA et al (2021) Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). Cancer 127(13):2204–2212PubMed
Hasanov E, Yeboa DN, Tucker MD et al (2022) An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA Cancer J Clin 72(5):454–489PubMed
Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 27:5794–5799PubMed
Heng DY, Xie W, Regan MM et al (2013) External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol 14(2):141–148PubMedPubMedCentral
Heo JH, Park C, Ghosh S et al (2021) A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma. J Clin Pharm Ther 46(1):35–49PubMed
Hirsch L, Martinez Chanza N, Farah S et al (2021) Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma. JAMA Oncol 7(12):1815–1823PubMed
Hutson TE, Michaelson MD, Kuzel TM et al (2021) A single-arm, multicenter, phase 2 study of Lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 80(2):162–170PubMed
Iacovelli R, Modica D, Palazzo A et al (2015) Clinical outcome and prognostic factors in renal medullary carcinoma: A pooled analysis from 18 years of medical literature. Can Urol Assoc J 9(3–4):E172–E177PubMedPubMedCentral
Ippen FM, Mahadevan A, Wong ET et al (2015) Stereotactic radiosurgery for renal cancer brain metastasis: prognostic factors and the role of whole-brain radiation and surgical resection. J Oncol 2015:636918PubMedPubMedCentral
Ishihara H, Takagi T, Kondo T et al (2018) Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy. Int J Clin Oncol 23(3):559–567PubMed
Jessurun CAC, Hulsbergen AFC, de Wit AE et al (2021) The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis. Neuro Oncol 23(8):1261–1272PubMedPubMedCentral
Jung KS, Lee SJ, Park SH et al (2018) Pazopanib for the treatment of non-clear cell renal cell carcinoma: a single-arm, open-label, multicenter Phase II Study. Cancer Res Treat 50(2):488–494PubMed
Karner C, Kew K, Wakefield V, Masento N, Edwards SJ (2019) Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis. BMJ Open 9(3):024691
Kilari D, Szabo A, Ghatalia P et al (2021) Outcomes with novel combinations in non-clear cell renal cell carcinoma(nccRCC): ORACLE study. J Clin Oncol 39:4580
Knox JJ, Barrios CH, Kim TM et al (2017) Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Ann Oncol 28(6):1339–1345PubMedPubMedCentral
Kushnir I, Basappa NS, Ghosh S et al (2021) Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clin Genitourin Cancer 19(6):521–530PubMed
Lee CH, Shah AY, Rasco D et al (2021a) Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol 22(7):946–958PubMedPubMedCentral
Lee JL, McDermott DF, Ziobro M et al (2021b) Pembrolizumab (pembro) monotherapy as first-line therapy in advanced noneclear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B. Ann Oncol 32(5):S687
Lee CH, Fitzgerald KN, Voss MH et al (2023) Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial. J Clin Oncol 41:4537
Leow JJ, Chong YL, Chang SL et al (2021) Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol 79(5):635–654PubMed
Levitin M, Ofori J, Shin WJ et al (2020) Radiation and checkpoint inhibitor immunotherapy lead to long term disease control in a metastatic RCC patient with brain metastases. Front Oncol 10:566070PubMedPubMedCentral
Lindner AK, Tulchiner G, Seeber A et al (2022) Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma. Front Oncol 12:906014PubMedPubMedCentral
Lorange JP, Ramirez Garcia Luna J, Grou-Boileau F et al (2023) Management of bone metastasis with zoledronic acid: A systematic review and Bayesian network meta-analysis. J Bone Oncol 39:100470PubMedPubMedCentral
Lu Y, Song Y, Xu Y et al (2020) The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients. Transl Androl Urol 9(2):367–381PubMedPubMedCentral
Luke JJ, Robert C, Carlino MS et al (2022) Safety profile of adjuvant pembrolizumab (pembro) in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC): Pooled analysis of phase III clinical trials. Ann Oncol 16:100102
Matsui Y (2020) Current multimodality treatments against brain metastases from renal cell carcinoma. Cancers (basel) 12(10):2875PubMed
Meyer E, Pasquier D, Bernadou G et al (2018) Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug group. Eur J Cancer 98:38–47PubMed
Monteiro FSM, Soares A, Rizzo A, Santoni M et al (2023) The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis. Clin Genitourin Cancer 21(3):324–333PubMed
Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456PubMed
Motzer RJ, Hutson TE, Cella D et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731PubMed
Motzer RJ, Escudier B, McDermott DF et al (2015a) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813PubMedPubMedCentral
Motzer RJ, Hutson TE, Glen H et al (2015b) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16(15):1473–1482PubMed
Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290PubMedPubMedCentral
Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1103–1115PubMedPubMedCentral
Motzer RJ, Escudier B, George S et al (2020) Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer 126(18):4156–4167PubMed
Motzer R, Alekseev B, Rha SY et al (2021a) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289–1300PubMed
Motzer RJ, Choueiri TK, Powles T et al (2021b) Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. J Clin Oncol 39:308
Motzer RJ, Russo P, Haas N et al (2021c) Adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: final overall survival analysis of the phase 3 PROTECT trial. Eur Urol 79(3):334–338PubMedPubMedCentral
Motzer RJ, McDermott DF, Escudier B et al (2022a) Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 128(11):2085–2097PubMed
Motzer RJ, Powles T, Burotto M et al (2022b) Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol 23(7):888–898PubMedPubMedCentral
Motzer RJ, Porta C, Eto M et al (2023a) Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol 41:4502–4502
Motzer RJ, Russo P, Grünwald V et al (2023b) Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet 401(10379):821–832PubMedPubMedCentral
Mourão TC, Curado MP, de Oliveira RAR et al (2022) Epidemiology of urological cancers in brazil: trends in mortality rates over more than two decades. J Epidemiol Glob Health 12(3):239–247PubMedPubMedCentral
Nabors LB, Portnow J, Ammirati M et al (2014) Central nervous system cancers, version 2. 2014. Featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw 12:1517–1523
Nasser SM, Sahal A, Hamad A, Elazzazy S (2019) Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study. J Oncol Pharm Pract 25(8):1846–1852PubMedPubMedCentral
Nieder C, Spanne O, Mehta MP, Grosu AL, Geinitz H (2011) Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years? Cancer 117(11):2505–2512PubMed
Nizam A, Schindelheim JA, Ornstein MC (2020) The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer Treat Res Commun 23:100169PubMed
Osterman CK, Rose TL (2020) A systematic review of systemic treatment options for advanced non-clear cell renal cell carcinoma. Kidney Cancer 4(1):15–27PubMedPubMedCentral
Pal SK, Tangen C, Thompson IM Jr et al (2021) A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet 397(10275):695–703PubMedPubMedCentral
Pal SK, Albiges L, Tomczak P et al (2023) Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet 402(10397):185–195PubMed
Park I, Lee JL, Ahn JH et al (2014) Active surveillance for metastatic or recurrent renal cell carcinoma. J Cancer Res Clin Oncol 140(8):1421–1428PubMed
Polascik TJ, Mouraviev V (2008) Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag 4(1):261–268PubMedPubMedCentral
Powles T, Tomczak P, Park SH et al (2022) Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23(9):1133–1144PubMed
Rassy E, Flippot R, Albiges L (2020) Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol 12:1758835920907504PubMedPubMedCentral
Ravaud A, Motzer RJ, Pandha HS et al (2016) Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 375(23):2246–2254PubMed
Raychaudhuri R, Riese MJ, Bylow K et al (2017) Immune check point inhibition in sarcomatoid renal cell carcinoma: a new treatment paradigm. Clin Genitourin Cancer 15(5):e897–e901PubMed
Rini BI, Dorff TB, Elson P et al (2016) Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol 17(9):1317–1324PubMedPubMedCentral
Rini BI, Plimack ER, Stus V et al (2019a) Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol 37:4500
Rini BI, Plimack ER, Stus V et al (2019b) Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 380(12):1116–1127PubMed
Rini BI, Plimack ER, Stus V et al (2023) Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426. J Clin Oncol 41:LBA4501
Ryan CW, Tangen C, Heath EI et al (2022) EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249). J Clin Oncol 40:LBA4500
Sameh WM, Hashad MM, Eid AA, Abou Yousif TA, Atta MA (2012) Recurrence pattern in patients with locally advanced renal cell carcinoma: The implications of clinicopathological variables. Arab J Urol 10(2):131–137PubMedPubMedCentral
Santoni M, Aurilio G, Massari F et al (2022) Nivolumab versus cabozantinib as second-line therapy in patients with advanced renal cell carcinoma: a real-world comparison. Clin Genitourin Cancer 20(3):285–295PubMed
Santoni M, Massari F, Myint ZW et al (2023) Global real-world outcomes of patients receiving immuno-oncology combinations for advanced renal cell carcinoma: the ARON-1 study. Target Oncol 18(4):559–570PubMed
Shah AY, Kotecha RR, Lemke EA et al (2019) Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer 114:67–75PubMedPubMedCentral
Sharma T, Tajzler C, Kapoor A (2018) Is there a role for adjuvant therapy after surgery in “High Risk for Recurrence” Kidney Cancer? an update on current concepts. Curr Oncol 25(5):444–453
Siegel RL, Miller KD, Wagle NS (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17–48PubMed
Sneed GT, Lee S, Brown JN, Hammond JM (2019) The role of pazopanib in non-clear cell renal cell carcinoma: a systematic review. Clin Genitourin Cancer 17(6):419–424PubMed
Soares A, Monteiro FSM, Maluf FC et al (2020) Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG). J Cancer Res Clin Oncol 146(7):1829–1845PubMedPubMedCentral
Srinivasan R, Gurram S, Al Harthy M et al (2020) Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. JCO 38:5004
Sun M, De Velasco G, Brastianos PK et al (2019) The development of brain metastases in patients with renal cell carcinoma: epidemiologic trends, survival, and clinical risk factors using a population-based cohort. Eur Urol Focus 5(3):474–481PubMed
Tannir NM, Plimack E, Ng C et al (2012) A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 62(6):1013–1019PubMed
Tannir NM, Jonasch E, Albiges L et al (2016) Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol 69(5):866–874PubMed
Tannir NM, Signoretti S, Choueiri TK et al (2021) Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res 27(1):78–86PubMed
Tenold M, Ravi P, Kumar M et al (2020) Current approaches to the treatment of advanced or metastatic renal cell carcinoma. Am Soc Clin Oncol Educ Book 40:1–10PubMed
Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC (2009) Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 181(2):518–523PubMed
Tran J, Ornstein MC (2022) Clinical review on the management of metastatic renal cell carcinoma. JCO Oncol Pract 18(3):187–196PubMed
Tykodi SS, Gordan LN, Alter RS et al (2022) Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. J Immunother Cancer 10(2):e003844PubMedPubMedCentral
Unnithan JS, Choueiri T, Garcia J et al (2007) Safety of VEGF-targeted tyrosine kinase inhibitors in patients (Pts) with metastatic renal cell carcinoma (mRCC) and central nervous system (CNS) metastases. J Clin Oncol 25:5047
Vera-Badillo FE, Templeton AJ, Duran I et al (2015) Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol 67(4):740–749PubMed
Wei Q, He H, Lv L, Xu X, Sun W (2020) The promising role of radiotherapy in the treatment of advanced or metastatic renal cell carcinoma: a narrative review. Transl Androl Urol 9(6):2821–2830PubMedPubMedCentral
Wiecek W, Karcher H (2016) Nivolumab versus cabozantinib: comparing overall survival in metastatic renal cell carcinoma. PLoS ONE 11(6):e0155389PubMedPubMedCentral
Wong ECL, Kapoor A (2020) Does bone-targeted therapy benefit patients with metastatic renal cell carcinoma? Transl Oncol 13(2):241–244PubMed
Wood SL, Brown JE (2012) Skeletal metastasis in renal cell carcinoma: current and future management options. Cancer Treat Rev 38(4):284–291PubMed
Yang J, Wang K, Yang Z (2023) Treatment strategies for clear cell renal cell carcinoma: past, present and future. Front Oncol 13:1133832PubMedPubMedCentral
Metadata
Title
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update
Authors
Andrey Soares
Fernando Sabino Marques Monteiro
Karine Martins da Trindade
Adriano Gonçalves e Silva
Ana Paula Garcia Cardoso
André Deeke Sasse
André P. Fay
André Paternò Castello Dias Carneiro
Antonio Machado Alencar Junior
Augusto César de Andrade Mota
Bruno Santucci
Daniel da Motta Girardi
Daniel Herchenhorn
Daniel Vilarim Araújo
Denis Leonardo Jardim
Diogo Assed Bastos
Diogo Rodrigues Rosa
Fabio A. Schutz
Fábio Roberto Kater
Felipe da Silva Marinho
Fernando Cotait Maluf
Fernando Nunes Galvão de Oliveira
Fernando Vidigal
Igor Alexandre Protzner Morbeck
Jose Augusto Rinck Júnior
Leonardo Atem G. A. Costa
Manuel Caitano Dias Ferreira Maia
Manuela Zereu
Marcelo Roberto Pereira Freitas
Mariane Sousa Fontes Dias
Milena Shizue Tariki
Pamela Muniz
Patrícia Medeiros Milhomem Beato
Paulo Sérgio Moraes Lages
Pedro Isaacsson Velho
Ricardo Saraiva de Carvalho
Rodrigo Coutinho Mariano
Sandro Roberto de Araújo Cavallero
Thiago Martins Oliveira
Vinicius Carrera Souza
Oren Smaletz
Stênio de Cássio Zequi
Publication date
01-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 4/2024
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-024-05663-z

Other articles of this Issue 4/2024

Journal of Cancer Research and Clinical Oncology 4/2024 Go to the issue

Research

Artesunate attenuates the tumorigenesis of choroidal melanoma via inhibiting EFNA3 through Stat3/Akt signaling pathway

Research

Safety and clinical efficacy of immune checkpoint inhibitors in advanced gastric cancer in the real world

Research

Prognostic impact of metabolic syndrome in patients with primary endometrial cancer: a retrospective bicentric study

Review

Unveiling the promising anticancer effect of copper-based compounds: a comprehensive review

Research

An algorithm-based technique for counting mitochondria in cells using immunohistochemical staining of formalin-fixed and paraffin-embedded sections

Research

Identification and validation of a lactate metabolism-related six-gene prognostic signature in intrahepatic cholangiocarcinoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits